All In Biotech

NDA 207155 · Acrotech Biopharma

Evomela

Melphalan Hydrochloride · Intravenous

Orphan

Last checked: Nov 19, 2026Latest source record: Apr 26, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Mar 10, 2016

Approved uses

2

Original approval plus efficacy supplements

Registered trials

903

155 Phase 3, 91 recruiting

FAERS reports

22,969

22,377 serious, 5,247 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEVERE BONE MARROW SUPPRESSION, HYPERSENSITIVITY, and LEUKEMOGENICITY Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing intravenous (IV) melphalan to oral melphalan have shown more myelosuppression with the IV formulation. Monitor hematologic laboratory parameters. [see Warnings and Precautions ( 5.1 )] Hypersensitivity reactions, including anaphylaxis, have occurred in approximately 2% of patients who received the IV formulation of melphalan. Discontinue treatment with Evomela for serious hypersensitivity reactions. [see Warnings and Precautions ( 5.4 )] Melphalan produces chromosomal aberrations in vitro and in vivo. Evomela should be considered potentially leukemogenic in humans. [see Warnings and Precautions ( 5.5 )] WARNING: SEVERE BONE MARROW SUPPRESSION, HYPERSENSITIVITY, AND LEUKEMOGENICITY See full prescribing...

What it is approved for

From the label in effect Sep 15, 2026.

Evomela is an alkylating drug indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. ( 1.1 ) 1.1 Multiple Myeloma-Conditioning Treatment Evomela is indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.

Mechanism: Melphalan is an alkylating agent of the bischloroethylamine type. As a result, its cytotoxicity appears to be related to the extent of its interstrand cross-linking with DNA, probably by binding at the N 7 position of guanine. Like other bifunctional alkylating agents, it is active against both resting and rapidly dividing tumor cells.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 10, 2016 Original approval · Efficacy Review
  • Mar 10, 2016 Original approval · Type 5 - New Formulation or New Manufacturer OrphanReviewLabelLetter
1 products under this application
  • EVOMELA · MELPHALAN HYDROCHLORIDE EQ 50MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Melphalan" as an intervention, any sponsor and status, largest first.

All 903 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,484
  • drug ineffective1,400
  • plasma cell myeloma1,286
  • febrile neutropenia1,255
  • mucosal inflammation1,148
  • neutropenia1,124
  • pyrexia1,071
  • pneumonia1,066
  • thrombocytopenia1,048
  • diarrhoea1,016
  • product use in unapproved indication929
  • sepsis809

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004156
2005324
2006216
2007211
2008320
2009369
2010181
2011531
2012458
2013772
2014898
20151,161
20161,184
20171,236
20181,681
20191,868
20201,937
20211,961
20221,538
20231,964
20241,736
20251,262
20261,005

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Evomela (Melphalan HCL/Betadex Sbes) · HCPCS J9246

2024 spending

$646K

Beneficiaries

137

147 claims

Per beneficiary

$4,712

2024 ASP limit $16.45 per unit

View as table
YearSpending
2020$367,602
2021$415,076
2022$612,418
2023$660,795
2024$645,527

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,635 on PubMed

Sponsor: Acrotech Biopharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.